*仅供医学专业人士阅读参考 自身免疫性疾病(AD)患者因免疫功能低下,同时使用糖皮质激素、免疫抑制剂及生物制剂等药物,增加了IFD的感染风险。临床医师应未雨绸缪,熟知AD患者IFD的危险因素和常用药物选择抗真菌药物。 另一方面,IFD的发病可伴随发热、中性粒细胞减少等症,而AD本身也可常见发热、中性粒细胞减少等症状,从而导致临床上对IFD的误诊、漏诊。因此,临床医师还应未雨绸缪,熟知AD患者IFD的危险因素,以便及时行IFD相关检查以帮助完善诊断与鉴别诊断。 念珠菌、曲霉、隐球菌是AD患者IFD的主要致病真菌 侵袭性念珠菌病(IC) 侵袭性曲霉病(IA) 隐球菌病 需注意,AMB类药物联用氟胞嘧啶时,可能会增加肾脏毒性[21]。而AMB类药物与其他具有肾毒性的药物同时使用,同样也会增加肾毒性。因此对于需要联合使用其他肾毒性药物的患者,如联用钙调磷酸酶抑制剂(CNI)时,建议密切监测肾功能[21],同时选择AMB同类药物中肾毒性较小的L-AmB,尽可能减少肾毒性影响[11]。 毛霉病等其他少见真菌病 *本材料的目的是通过介绍有关医学和科学信息和进展,提高医学专业人士的医学知识。因此,本材料仅供医学专业人士使用。本材料并非药品广告。读者不应参考或依赖本材料的任何内容,做出购买或使用任何药品的任何决定。 欢迎关注“吉智医” [1]Chapter 2 - Invasive fungal diseases in patients with rheumatic diseases.Handbook of Systemic Autoimmune Diseases.Volume 16, 2020, Pages 13-48 [2]Su CF, Lai CC, Li TH, et al. Epidemiology and risk of invasive fungal infections in systemic lupus erythematosus: a nationwide population-based cohort study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211058502. Published 2021 Nov 23. [3]Vaquero-Herrero MP, Ragozzino S, Iriart X, et al. Candida bloodstream infection in patients with systemic autoimmune diseases. Med Mal Infect. 2020;50(4):372-376. [4]Nguyen S, Truong JQ, Bruning JB. Targeting Unconventional Pathways in Pursuit of Novel Antifungals. Front Mol Biosci. 2021;7:621366. Published 2021 Jan 12. [5] Xiao M, Chen SC, Kong F, et al. Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: An Update From the CHIF-NET Study. J Infect Dis. 2020;221(Suppl 2):S139-S147. [6]Mareković I, Pleško S, Rezo Vranješ V, Herljević Z, Kuliš T, Jandrlić M. Epidemiology of Candidemia: Three-Year Results from a Croatian Tertiary Care Hospital. J Fungi (Basel). 2021;7(4):267. Published 2021 Mar 31. [7]Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. [8]Bougnoux ME, Angebault C, Paccoud O, Coignard H, Lanternier F, Lortholary O. Impact of intravenous and subcutaneous immunoglobulins on false positivity of galactomannan and β-D-glucan antigenaemia and detection of circulating Aspergillus fumigatus DNA. Clin Microbiol Infect. 2020;26(8):1101-1102. [9]Hung YH, Lai HH, Lin HC, Sun KS, Chen CY. Investigating Factors of False-Positive Results of Aspergillus Galactomannan Assay: A Case-Control Study in Intensive Care Units. Front Pharmacol. 2021;12:747280. Published 2021 Dec 20. [10]Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clin Infect Dis. 2019;68(Suppl 4):S244-S259. [11]孔旭东, 王晓星, 陈玥,等. 两性霉素B不同制剂的药学特性和临床应用[J]. 临床药物治疗杂志, 2022, 20(7):6.. [12]Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. [13]Warris A, Lehrnbecher T, Roilides E, Castagnola E, Brüggemann RJM, Groll AH. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microbiol Infect. 2019;25(9):1096-1113. [14]杜敏, 江振洲, 张陆勇. 常用免疫抑制剂致肝损伤的研究进展[J]. 药物评价研究, 2022, 45(5):7. [15]Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. EXPERT OPIN DRUG SAF 2017, 16(2): 149-165. [16]苏丹, 陈露, 张蕾,等. 环孢素与唑类抗真菌药物相互作用的研究进展[J]. 广西医学, 2020, 42(5):3. [17]ECCMID 2022 报告:One Health and mycology: what are the significant and potential interactions between agriculture and human health? [18]Verweij PE, Ananda-Rajah M, Andes D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat. 2015;21-22:30-40. [19]Marr KA, Sun Y, Spec A, et al. A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative People in the United States. Clin Infect Dis. 2020;70(2):252-261. [20]浙江省医学会热带病和寄生虫病分会艾滋病学组. 艾滋病患者隐球菌感染筛查浙江省专家共识[J]. 中华临床感染病杂志, 2019, 12(2):7. [21]AmBisome (amphotericin B) liposome for injection [22]Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. [23]Kotani T, Takeuchi T, Makino S, et al. Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease. J Infect Chemother. 2013;19(4):691-697. 此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场 |
|